Canada markets open in 3 hours 12 minutes
  • S&P/TSX

    21,162.65
    +301.55 (+1.45%)
     
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • DOW

    35,719.43
    +492.40 (+1.40%)
     
  • CAD/USD

    0.7913
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    71.13
    -0.92 (-1.28%)
     
  • BTC-CAD

    62,209.42
    -3,171.58 (-4.85%)
     
  • CMC Crypto 200

    1,280.26
    -41.02 (-3.10%)
     
  • GOLD FUTURES

    1,793.60
    +8.90 (+0.50%)
     
  • RUSSELL 2000

    2,253.79
    +50.31 (+2.28%)
     
  • 10-Yr Bond

    1.4800
    0.0000 (0.00%)
     
  • NASDAQ futures

    16,357.00
    +39.00 (+0.24%)
     
  • VOLATILITY

    22.44
    -4.74 (-17.44%)
     
  • FTSE

    7,337.89
    -2.01 (-0.03%)
     
  • NIKKEI 225

    28,860.62
    +405.02 (+1.42%)
     
  • CAD/EUR

    0.7007
    -0.0007 (-0.10%)
     

Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

·6 min read
Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting